Positions

Selected Publications

Academic Article

Year Title Altmetric
2021 Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumorsOncogenesis.  10. 2021
2021 Anti-SSTR2 antibody-drug conjugate for neuroendocrine tumor therapyCancer Gene Therapy.  28:799-812. 2021
2021 Psychomotor impairments and therapeutic implications revealed by a mutation associated with infantile Parkinsonism-DystoniaeLife.  10. 2021
2020 Phosphoprotein-based biomarkers as predictors for cancer therapyProceedings of the National Academy of Sciences of USA.  117:18401-18411. 2020
2018 Preclinical characterization of tyrosine kinase inhibitor-based targeted therapies for neuroendocrine thyroid cancerOncotarget.  9:37662-37675. 2018
2018 Biomimetic nanoparticles with enhanced affinity towards activated endothelium as versatile tools for theranostic drug deliveryTheranostics.  8:1131-1145. 2018
2014 Regulated localization is sufficient for hormonal control of regulator of G protein signaling homology Rho guanine nucleotide exchange factors (RH-RhoGEFs).Journal of Biological Chemistry.  289:19737-19746. 2014
2013 Activated RhoA is a positive feedback regulator of the Lbc family of Rho guanine nucleotide exchange factor proteins.Journal of Biological Chemistry.  288:11325-11333. 2013
Bile acids gate dopamine transporter mediated currents
Cdk5 drives formation of heterogeneous pancreatic neuroendocrine tumors

Chapter

Year Title Altmetric
2007 Regulation of Rho guanine nucleotide exchange factors by G proteins..  189-228. 2007

Education And Training

  • Doctor of Philosophy in Cell / Cellular Biology and Anatomical Sciences, The University of Texas Southwestern Medical Center at Dallas 2013
  • Full Name

  • Angela Carter